Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues
- 1 April 2016
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pancreas
- Vol. 45 (4), 613-619
- https://doi.org/10.1097/mpa.0000000000000521
Abstract
Objectives Studies have proposed pro-oncogenic effects of glucagon-like peptide-1 receptor (GLP-1R) agonists in the pancreas by promoting GLP-1R overactivation in pancreatic cells. However, the expression of GLP-1R in normal and neoplastic pancreatic cells remains poorly defined, and reliable methods for detecting GLP-1R in tissue specimens are needed. Methods We used RNA in situ hybridization to quantify glp-1r RNA in surgically resected human pancreatic specimens, including pancreatic ductal adenocarcinoma (PDAC), preinvasive intraepithelial lesions (pancreatic intraepithelial neoplasia), and non-neoplastic ductal, acinar, and endocrine cells. A mixed-effect linear regression model was used to investigate the relationship between glp-1r signals and all cells, ordered by increasing grade of dysplasia. Results All cell types had evidence of glp-1r transcripts, with the highest expression in endocrine cells and lowest in ductal cells. The slope of the fitted line was not significantly different from zero (0.07; 95% confidence interval, −0.0094 to 0.244; P = 0.39), suggesting that progression from normal cells to PDAC is not associated with a parallel increase in glp-1r RNA. A series of pairwise comparisons between all cell types with respect to their glp-1r expression showed no significant difference in glp-1r in cancer, pancreatic intraepithelial neoplasia, and acinar and ductal cells. Conclusions Our study supports the lack of evidence for GLP-1R overexpression in PDAC.Keywords
This publication has 39 references indexed in Scilit:
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 2013
- Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical StudiesDiabetes Therapy, 2013
- GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressureNature Medicine, 2013
- Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studiesJournal of Translational Medicine, 2013
- The Glucagon-Like Peptide-1 Receptor—or Not?Endocrinology, 2013
- Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated miceRegulatory Peptides, 2012
- Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12D Mouse ModelDiabetes, 2012
- The Human GLP-1 Analog Liraglutide and the PancreasDiabetes, 2012
- β-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in miceJCI Insight, 2010
- Glucagon-like Peptide-2 Does Not Modify the Growth or Survival of Murine or Human Intestinal Tumor CellsCancer Research, 2008